Extreme Tumor Mutational Burden Predicts Near-Curative Outcomes With Checkpoint Immunotherapy in Melanoma: Half the Eligible, Half the Cure.

Abstract excerpt

Tumor-mutational burden (TMB) is a mechanistic surrogate of neo-antigen load and thus a plausible biomarker for response to immune checkpoint blockade (ICB). In melanoma, however, the extreme right tail of the mutational spectrum, known as "hypermutation," remains poorly characterized. This study sought to explore an a priori threshold of hypermutation that would delineate a subgroup with extraordinary benefit...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to IMPACT gene
• Share to Immune Checkpoint Inhibitors